nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—SLC6A4—chronic obstructive pulmonary disease	0.168	0.35	CbGaD
Fluvoxamine—CYP1A1—chronic obstructive pulmonary disease	0.158	0.331	CbGaD
Fluvoxamine—CYP1A2—chronic obstructive pulmonary disease	0.153	0.319	CbGaD
Fluvoxamine—CYP2E1—Aminophylline—chronic obstructive pulmonary disease	0.0369	0.113	CbGbCtD
Fluvoxamine—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0272	0.0832	CbGbCtD
Fluvoxamine—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0272	0.0832	CbGbCtD
Fluvoxamine—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0226	0.0692	CbGbCtD
Fluvoxamine—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0226	0.0692	CbGbCtD
Fluvoxamine—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0214	0.0653	CbGbCtD
Fluvoxamine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0207	0.0633	CbGbCtD
Fluvoxamine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0207	0.0633	CbGbCtD
Fluvoxamine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0185	0.0564	CbGbCtD
Fluvoxamine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0174	0.0531	CbGbCtD
Fluvoxamine—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0172	0.0524	CbGbCtD
Fluvoxamine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0117	0.0359	CbGbCtD
Fluvoxamine—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0114	0.035	CbGbCtD
Fluvoxamine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0112	0.0342	CbGbCtD
Fluvoxamine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00998	0.0305	CbGbCtD
Fluvoxamine—ABCB1—Prednisolone—chronic obstructive pulmonary disease	0.00977	0.0299	CbGbCtD
Fluvoxamine—ABCB1—Prednisone—chronic obstructive pulmonary disease	0.00923	0.0282	CbGbCtD
Fluvoxamine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00585	0.0179	CbGbCtD
Fluvoxamine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00553	0.0169	CbGbCtD
Fluvoxamine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000101	0.000683	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000101	0.000682	CcSEcCtD
Fluvoxamine—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000682	CcSEcCtD
Fluvoxamine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.0001	0.000674	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	9.97e-05	0.000671	CcSEcCtD
Fluvoxamine—Oedema—Salbutamol—chronic obstructive pulmonary disease	9.97e-05	0.000671	CcSEcCtD
Fluvoxamine—Infection—Salbutamol—chronic obstructive pulmonary disease	9.9e-05	0.000667	CcSEcCtD
Fluvoxamine—Hypotension—Formoterol—chronic obstructive pulmonary disease	9.87e-05	0.000664	CcSEcCtD
Fluvoxamine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	9.87e-05	0.000664	CcSEcCtD
Fluvoxamine—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	9.86e-05	0.000664	CcSEcCtD
Fluvoxamine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	9.81e-05	0.000661	CcSEcCtD
Fluvoxamine—Shock—Salbutamol—chronic obstructive pulmonary disease	9.81e-05	0.00066	CcSEcCtD
Fluvoxamine—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	9.79e-05	0.00066	CcSEcCtD
Fluvoxamine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	9.78e-05	0.000658	CcSEcCtD
Fluvoxamine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	9.73e-05	0.000655	CcSEcCtD
Fluvoxamine—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	9.72e-05	0.000655	CcSEcCtD
Fluvoxamine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	9.64e-05	0.000649	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	9.64e-05	0.000649	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	9.62e-05	0.000648	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	9.62e-05	0.000648	CcSEcCtD
Fluvoxamine—Insomnia—Formoterol—chronic obstructive pulmonary disease	9.55e-05	0.000643	CcSEcCtD
Fluvoxamine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	9.55e-05	0.000643	CcSEcCtD
Fluvoxamine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	9.5e-05	0.00064	CcSEcCtD
Fluvoxamine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	9.49e-05	0.000639	CcSEcCtD
Fluvoxamine—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	9.45e-05	0.000636	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	9.42e-05	0.000634	CcSEcCtD
Fluvoxamine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	9.41e-05	0.000634	CcSEcCtD
Fluvoxamine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	9.41e-05	0.000634	CcSEcCtD
Fluvoxamine—Somnolence—Formoterol—chronic obstructive pulmonary disease	9.39e-05	0.000632	CcSEcCtD
Fluvoxamine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	9.39e-05	0.000632	CcSEcCtD
Fluvoxamine—Insomnia—Montelukast—chronic obstructive pulmonary disease	9.35e-05	0.00063	CcSEcCtD
Fluvoxamine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	9.32e-05	0.000627	CcSEcCtD
Fluvoxamine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	9.29e-05	0.000626	CcSEcCtD
Fluvoxamine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	9.29e-05	0.000626	CcSEcCtD
Fluvoxamine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	9.29e-05	0.000625	CcSEcCtD
Fluvoxamine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	9.26e-05	0.000623	CcSEcCtD
Fluvoxamine—Injury—Prednisone—chronic obstructive pulmonary disease	9.2e-05	0.000619	CcSEcCtD
Fluvoxamine—Somnolence—Montelukast—chronic obstructive pulmonary disease	9.19e-05	0.000619	CcSEcCtD
Fluvoxamine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	9.17e-05	0.000618	CcSEcCtD
Fluvoxamine—Weight increased—Prednisolone—chronic obstructive pulmonary disease	9.15e-05	0.000616	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	9.12e-05	0.000614	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	9.12e-05	0.000614	CcSEcCtD
Fluvoxamine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	9.1e-05	0.000613	CcSEcCtD
Fluvoxamine—Fatigue—Formoterol—chronic obstructive pulmonary disease	9.1e-05	0.000613	CcSEcCtD
Fluvoxamine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	9.1e-05	0.000613	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	9.08e-05	0.000612	CcSEcCtD
Fluvoxamine—Pain—Arformoterol—chronic obstructive pulmonary disease	9.03e-05	0.000608	CcSEcCtD
Fluvoxamine—Constipation—Formoterol—chronic obstructive pulmonary disease	9.03e-05	0.000608	CcSEcCtD
Fluvoxamine—Pain—Formoterol—chronic obstructive pulmonary disease	9.03e-05	0.000608	CcSEcCtD
Fluvoxamine—Constipation—Arformoterol—chronic obstructive pulmonary disease	9.03e-05	0.000608	CcSEcCtD
Fluvoxamine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	9.02e-05	0.000607	CcSEcCtD
Fluvoxamine—Amnesia—Prednisone—chronic obstructive pulmonary disease	9e-05	0.000606	CcSEcCtD
Fluvoxamine—Increased appetite—Prednisone—chronic obstructive pulmonary disease	9e-05	0.000606	CcSEcCtD
Fluvoxamine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	8.95e-05	0.000603	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	8.93e-05	0.000601	CcSEcCtD
Fluvoxamine—Fatigue—Montelukast—chronic obstructive pulmonary disease	8.92e-05	0.0006	CcSEcCtD
Fluvoxamine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	8.89e-05	0.000599	CcSEcCtD
Fluvoxamine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	8.86e-05	0.000597	CcSEcCtD
Fluvoxamine—Pain—Montelukast—chronic obstructive pulmonary disease	8.84e-05	0.000596	CcSEcCtD
Fluvoxamine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	8.84e-05	0.000595	CcSEcCtD
Fluvoxamine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	8.82e-05	0.000594	CcSEcCtD
Fluvoxamine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	8.79e-05	0.000592	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	8.79e-05	0.000592	CcSEcCtD
Fluvoxamine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	8.78e-05	0.000591	CcSEcCtD
Fluvoxamine—Purpura—Prednisone—chronic obstructive pulmonary disease	8.77e-05	0.000591	CcSEcCtD
Fluvoxamine—Rash—Aminophylline—chronic obstructive pulmonary disease	8.75e-05	0.000589	CcSEcCtD
Fluvoxamine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	8.74e-05	0.000588	CcSEcCtD
Fluvoxamine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	8.71e-05	0.000587	CcSEcCtD
Fluvoxamine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	8.7e-05	0.000586	CcSEcCtD
Fluvoxamine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	8.7e-05	0.000586	CcSEcCtD
Fluvoxamine—Headache—Aminophylline—chronic obstructive pulmonary disease	8.69e-05	0.000585	CcSEcCtD
Fluvoxamine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	8.67e-05	0.000584	CcSEcCtD
Fluvoxamine—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	8.66e-05	0.000583	CcSEcCtD
Fluvoxamine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	8.65e-05	0.000583	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	8.63e-05	0.000581	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	8.63e-05	0.000581	CcSEcCtD
Fluvoxamine—Lethargy—Prednisone—chronic obstructive pulmonary disease	8.63e-05	0.000581	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	8.61e-05	0.00058	CcSEcCtD
Fluvoxamine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	8.6e-05	0.000579	CcSEcCtD
Fluvoxamine—Constipation—Salbutamol—chronic obstructive pulmonary disease	8.53e-05	0.000574	CcSEcCtD
Fluvoxamine—Pain—Salbutamol—chronic obstructive pulmonary disease	8.53e-05	0.000574	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	8.46e-05	0.000569	CcSEcCtD
Fluvoxamine—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	8.45e-05	0.000569	CcSEcCtD
Fluvoxamine—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	8.45e-05	0.000569	CcSEcCtD
Fluvoxamine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	8.39e-05	0.000565	CcSEcCtD
Fluvoxamine—Urticaria—Formoterol—chronic obstructive pulmonary disease	8.39e-05	0.000565	CcSEcCtD
Fluvoxamine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	8.35e-05	0.000562	CcSEcCtD
Fluvoxamine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	8.35e-05	0.000562	CcSEcCtD
Fluvoxamine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	8.35e-05	0.000562	CcSEcCtD
Fluvoxamine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	8.35e-05	0.000562	CcSEcCtD
Fluvoxamine—Affect lability—Prednisone—chronic obstructive pulmonary disease	8.32e-05	0.00056	CcSEcCtD
Fluvoxamine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	8.32e-05	0.00056	CcSEcCtD
Fluvoxamine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	8.26e-05	0.000556	CcSEcCtD
Fluvoxamine—Rash—Tiotropium—chronic obstructive pulmonary disease	8.25e-05	0.000555	CcSEcCtD
Fluvoxamine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	8.24e-05	0.000555	CcSEcCtD
Fluvoxamine—Nausea—Aminophylline—chronic obstructive pulmonary disease	8.24e-05	0.000555	CcSEcCtD
Fluvoxamine—Urticaria—Montelukast—chronic obstructive pulmonary disease	8.22e-05	0.000553	CcSEcCtD
Fluvoxamine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	8.22e-05	0.000553	CcSEcCtD
Fluvoxamine—Headache—Tiotropium—chronic obstructive pulmonary disease	8.2e-05	0.000552	CcSEcCtD
Fluvoxamine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	8.19e-05	0.000552	CcSEcCtD
Fluvoxamine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	8.18e-05	0.000551	CcSEcCtD
Fluvoxamine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	8.18e-05	0.000551	CcSEcCtD
Fluvoxamine—Face oedema—Prednisone—chronic obstructive pulmonary disease	8.16e-05	0.00055	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	8.15e-05	0.000549	CcSEcCtD
Fluvoxamine—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	8.09e-05	0.000545	CcSEcCtD
Fluvoxamine—Irritability—Prednisone—chronic obstructive pulmonary disease	8.07e-05	0.000543	CcSEcCtD
Fluvoxamine—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	8.05e-05	0.000542	CcSEcCtD
Fluvoxamine—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	8.04e-05	0.000541	CcSEcCtD
Fluvoxamine—Mood swings—Prednisone—chronic obstructive pulmonary disease	8.01e-05	0.000539	CcSEcCtD
Fluvoxamine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	7.92e-05	0.000533	CcSEcCtD
Fluvoxamine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	7.88e-05	0.000531	CcSEcCtD
Fluvoxamine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	7.88e-05	0.000531	CcSEcCtD
Fluvoxamine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	7.78e-05	0.000524	CcSEcCtD
Fluvoxamine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	7.78e-05	0.000524	CcSEcCtD
Fluvoxamine—Nausea—Tiotropium—chronic obstructive pulmonary disease	7.77e-05	0.000523	CcSEcCtD
Fluvoxamine—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	7.76e-05	0.000522	CcSEcCtD
Fluvoxamine—Dry skin—Prednisone—chronic obstructive pulmonary disease	7.75e-05	0.000522	CcSEcCtD
Fluvoxamine—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	7.69e-05	0.000518	CcSEcCtD
Fluvoxamine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	7.62e-05	0.000513	CcSEcCtD
Fluvoxamine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	7.58e-05	0.00051	CcSEcCtD
Fluvoxamine—Asthenia—Formoterol—chronic obstructive pulmonary disease	7.58e-05	0.00051	CcSEcCtD
Fluvoxamine—Pruritus—Formoterol—chronic obstructive pulmonary disease	7.47e-05	0.000503	CcSEcCtD
Fluvoxamine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	7.47e-05	0.000503	CcSEcCtD
Fluvoxamine—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	7.46e-05	0.000502	CcSEcCtD
Fluvoxamine—Asthenia—Montelukast—chronic obstructive pulmonary disease	7.42e-05	0.0005	CcSEcCtD
Fluvoxamine—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	7.36e-05	0.000495	CcSEcCtD
Fluvoxamine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	7.34e-05	0.000495	CcSEcCtD
Fluvoxamine—Pruritus—Montelukast—chronic obstructive pulmonary disease	7.32e-05	0.000493	CcSEcCtD
Fluvoxamine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	7.22e-05	0.000486	CcSEcCtD
Fluvoxamine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	7.22e-05	0.000486	CcSEcCtD
Fluvoxamine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	7.19e-05	0.000484	CcSEcCtD
Fluvoxamine—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	7.16e-05	0.000482	CcSEcCtD
Fluvoxamine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	7.15e-05	0.000482	CcSEcCtD
Fluvoxamine—Sweating increased—Prednisone—chronic obstructive pulmonary disease	7.12e-05	0.000479	CcSEcCtD
Fluvoxamine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	7.08e-05	0.000476	CcSEcCtD
Fluvoxamine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	7.05e-05	0.000475	CcSEcCtD
Fluvoxamine—Dizziness—Formoterol—chronic obstructive pulmonary disease	6.98e-05	0.00047	CcSEcCtD
Fluvoxamine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	6.98e-05	0.00047	CcSEcCtD
Fluvoxamine—Dizziness—Montelukast—chronic obstructive pulmonary disease	6.84e-05	0.000461	CcSEcCtD
Fluvoxamine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	6.82e-05	0.000459	CcSEcCtD
Fluvoxamine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	6.73e-05	0.000453	CcSEcCtD
Fluvoxamine—Vomiting—Formoterol—chronic obstructive pulmonary disease	6.71e-05	0.000452	CcSEcCtD
Fluvoxamine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	6.71e-05	0.000452	CcSEcCtD
Fluvoxamine—Rash—Arformoterol—chronic obstructive pulmonary disease	6.66e-05	0.000448	CcSEcCtD
Fluvoxamine—Rash—Formoterol—chronic obstructive pulmonary disease	6.66e-05	0.000448	CcSEcCtD
Fluvoxamine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	6.65e-05	0.000448	CcSEcCtD
Fluvoxamine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	6.65e-05	0.000448	CcSEcCtD
Fluvoxamine—Weight increased—Prednisone—chronic obstructive pulmonary disease	6.65e-05	0.000448	CcSEcCtD
Fluvoxamine—Headache—Arformoterol—chronic obstructive pulmonary disease	6.61e-05	0.000445	CcSEcCtD
Fluvoxamine—Headache—Formoterol—chronic obstructive pulmonary disease	6.61e-05	0.000445	CcSEcCtD
Fluvoxamine—Weight decreased—Prednisone—chronic obstructive pulmonary disease	6.61e-05	0.000445	CcSEcCtD
Fluvoxamine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	6.6e-05	0.000445	CcSEcCtD
Fluvoxamine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	6.59e-05	0.000444	CcSEcCtD
Fluvoxamine—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	6.59e-05	0.000444	CcSEcCtD
Fluvoxamine—Vomiting—Montelukast—chronic obstructive pulmonary disease	6.58e-05	0.000443	CcSEcCtD
Fluvoxamine—Rash—Montelukast—chronic obstructive pulmonary disease	6.52e-05	0.000439	CcSEcCtD
Fluvoxamine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	6.51e-05	0.000439	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	6.5e-05	0.000438	CcSEcCtD
Fluvoxamine—Depression—Prednisone—chronic obstructive pulmonary disease	6.5e-05	0.000437	CcSEcCtD
Fluvoxamine—Headache—Montelukast—chronic obstructive pulmonary disease	6.48e-05	0.000436	CcSEcCtD
Fluvoxamine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	6.42e-05	0.000432	CcSEcCtD
Fluvoxamine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	6.4e-05	0.000431	CcSEcCtD
Fluvoxamine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	6.39e-05	0.00043	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	6.39e-05	0.00043	CcSEcCtD
Fluvoxamine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	6.34e-05	0.000427	CcSEcCtD
Fluvoxamine—Malaise—Prednisolone—chronic obstructive pulmonary disease	6.32e-05	0.000425	CcSEcCtD
Fluvoxamine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	6.29e-05	0.000424	CcSEcCtD
Fluvoxamine—Rash—Salbutamol—chronic obstructive pulmonary disease	6.29e-05	0.000423	CcSEcCtD
Fluvoxamine—Syncope—Prednisolone—chronic obstructive pulmonary disease	6.28e-05	0.000423	CcSEcCtD
Fluvoxamine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	6.28e-05	0.000423	CcSEcCtD
Fluvoxamine—Nausea—Formoterol—chronic obstructive pulmonary disease	6.27e-05	0.000422	CcSEcCtD
Fluvoxamine—Nausea—Arformoterol—chronic obstructive pulmonary disease	6.27e-05	0.000422	CcSEcCtD
Fluvoxamine—Headache—Salbutamol—chronic obstructive pulmonary disease	6.25e-05	0.000421	CcSEcCtD
Fluvoxamine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	6.16e-05	0.000415	CcSEcCtD
Fluvoxamine—Nausea—Montelukast—chronic obstructive pulmonary disease	6.14e-05	0.000414	CcSEcCtD
Fluvoxamine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	6.07e-05	0.000409	CcSEcCtD
Fluvoxamine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	6.05e-05	0.000407	CcSEcCtD
Fluvoxamine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	5.95e-05	0.000401	CcSEcCtD
Fluvoxamine—Nausea—Salbutamol—chronic obstructive pulmonary disease	5.92e-05	0.000399	CcSEcCtD
Fluvoxamine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	5.89e-05	0.000397	CcSEcCtD
Fluvoxamine—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	5.88e-05	0.000396	CcSEcCtD
Fluvoxamine—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	5.85e-05	0.000394	CcSEcCtD
Fluvoxamine—Hallucination—Prednisone—chronic obstructive pulmonary disease	5.82e-05	0.000392	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	5.72e-05	0.000385	CcSEcCtD
Fluvoxamine—Oedema—Prednisolone—chronic obstructive pulmonary disease	5.72e-05	0.000385	CcSEcCtD
Fluvoxamine—Shock—Prednisolone—chronic obstructive pulmonary disease	5.63e-05	0.000379	CcSEcCtD
Fluvoxamine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	5.58e-05	0.000376	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	5.53e-05	0.000372	CcSEcCtD
Fluvoxamine—Eye disorder—Prednisone—chronic obstructive pulmonary disease	5.47e-05	0.000368	CcSEcCtD
Fluvoxamine—Angiopathy—Prednisone—chronic obstructive pulmonary disease	5.31e-05	0.000357	CcSEcCtD
Fluvoxamine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	5.22e-05	0.000352	CcSEcCtD
Fluvoxamine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	5.17e-05	0.000348	CcSEcCtD
Fluvoxamine—Alopecia—Prednisone—chronic obstructive pulmonary disease	5.17e-05	0.000348	CcSEcCtD
Fluvoxamine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	5.13e-05	0.000346	CcSEcCtD
Fluvoxamine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	5.12e-05	0.000345	CcSEcCtD
Fluvoxamine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	5.09e-05	0.000343	CcSEcCtD
Fluvoxamine—Pain—Prednisolone—chronic obstructive pulmonary disease	4.89e-05	0.000329	CcSEcCtD
Fluvoxamine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	4.8e-05	0.000323	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	4.72e-05	0.000318	CcSEcCtD
Fluvoxamine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	4.71e-05	0.000317	CcSEcCtD
Fluvoxamine—Anaemia—Prednisone—chronic obstructive pulmonary disease	4.71e-05	0.000317	CcSEcCtD
Fluvoxamine—Agitation—Prednisone—chronic obstructive pulmonary disease	4.68e-05	0.000315	CcSEcCtD
Fluvoxamine—Angioedema—Prednisone—chronic obstructive pulmonary disease	4.65e-05	0.000313	CcSEcCtD
Fluvoxamine—Malaise—Prednisone—chronic obstructive pulmonary disease	4.59e-05	0.000309	CcSEcCtD
Fluvoxamine—Vertigo—Prednisone—chronic obstructive pulmonary disease	4.57e-05	0.000308	CcSEcCtD
Fluvoxamine—Syncope—Prednisone—chronic obstructive pulmonary disease	4.57e-05	0.000307	CcSEcCtD
Fluvoxamine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	4.54e-05	0.000306	CcSEcCtD
Fluvoxamine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	4.47e-05	0.000301	CcSEcCtD
Fluvoxamine—Convulsion—Prednisone—chronic obstructive pulmonary disease	4.41e-05	0.000297	CcSEcCtD
Fluvoxamine—Hypertension—Prednisone—chronic obstructive pulmonary disease	4.4e-05	0.000296	CcSEcCtD
Fluvoxamine—Myalgia—Prednisone—chronic obstructive pulmonary disease	4.33e-05	0.000292	CcSEcCtD
Fluvoxamine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	4.33e-05	0.000292	CcSEcCtD
Fluvoxamine—Anxiety—Prednisone—chronic obstructive pulmonary disease	4.32e-05	0.000291	CcSEcCtD
Fluvoxamine—Discomfort—Prednisone—chronic obstructive pulmonary disease	4.28e-05	0.000288	CcSEcCtD
Fluvoxamine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	4.21e-05	0.000284	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	4.16e-05	0.00028	CcSEcCtD
Fluvoxamine—Oedema—Prednisone—chronic obstructive pulmonary disease	4.16e-05	0.00028	CcSEcCtD
Fluvoxamine—Infection—Prednisone—chronic obstructive pulmonary disease	4.13e-05	0.000278	CcSEcCtD
Fluvoxamine—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.12e-05	0.000909	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.09e-05	0.000903	CbGpPWpGaD
Fluvoxamine—Shock—Prednisone—chronic obstructive pulmonary disease	4.09e-05	0.000275	CcSEcCtD
Fluvoxamine—CYP3A5—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.08e-05	0.000901	CbGpPWpGaD
Fluvoxamine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	4.07e-05	0.000274	CcSEcCtD
Fluvoxamine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	4.06e-05	0.000273	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	4.02e-05	0.00027	CcSEcCtD
Fluvoxamine—CYP2B6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.01e-05	0.000886	CbGpPWpGaD
Fluvoxamine—Anorexia—Prednisone—chronic obstructive pulmonary disease	3.96e-05	0.000267	CcSEcCtD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	3.96e-05	0.000874	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.96e-05	0.000874	CbGpPWpGaD
Fluvoxamine—CYP2E1—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.93e-05	0.000868	CbGpPWpGaD
Fluvoxamine—CYP3A5—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.92e-05	0.000866	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	3.91e-05	0.000864	CbGpPWpGaD
Fluvoxamine—CYP1A1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.91e-05	0.000863	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.88e-05	0.000856	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.87e-05	0.000854	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	3.87e-05	0.000854	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.85e-05	0.000851	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.84e-05	0.000847	CbGpPWpGaD
Fluvoxamine—SLC6A4—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.83e-05	0.000846	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	3.8e-05	0.00084	CbGpPWpGaD
Fluvoxamine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	3.79e-05	0.000255	CcSEcCtD
Fluvoxamine—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.78e-05	0.000836	CbGpPWpGaD
Fluvoxamine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	3.78e-05	0.000255	CcSEcCtD
Fluvoxamine—Insomnia—Prednisone—chronic obstructive pulmonary disease	3.76e-05	0.000253	CcSEcCtD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	3.75e-05	0.000829	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	3.75e-05	0.000828	CbGpPWpGaD
Fluvoxamine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	3.73e-05	0.000251	CcSEcCtD
Fluvoxamine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	3.66e-05	0.000246	CcSEcCtD
Fluvoxamine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	3.61e-05	0.000243	CcSEcCtD
Fluvoxamine—Rash—Prednisolone—chronic obstructive pulmonary disease	3.61e-05	0.000243	CcSEcCtD
Fluvoxamine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	3.6e-05	0.000243	CcSEcCtD
Fluvoxamine—Fatigue—Prednisone—chronic obstructive pulmonary disease	3.58e-05	0.000241	CcSEcCtD
Fluvoxamine—Headache—Prednisolone—chronic obstructive pulmonary disease	3.58e-05	0.000241	CcSEcCtD
Fluvoxamine—Constipation—Prednisone—chronic obstructive pulmonary disease	3.55e-05	0.000239	CcSEcCtD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.53e-05	0.000779	CbGpPWpGaD
Fluvoxamine—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.48e-05	0.000768	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.43e-05	0.000758	CbGpPWpGaD
Fluvoxamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	3.43e-05	0.000758	CbGpPWpGaD
Fluvoxamine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	3.42e-05	0.000231	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	3.4e-05	0.000229	CcSEcCtD
Fluvoxamine—Nausea—Prednisolone—chronic obstructive pulmonary disease	3.4e-05	0.000229	CcSEcCtD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	3.39e-05	0.000749	CbGpPWpGaD
Fluvoxamine—Urticaria—Prednisone—chronic obstructive pulmonary disease	3.3e-05	0.000222	CcSEcCtD
Fluvoxamine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	3.28e-05	0.000221	CcSEcCtD
Fluvoxamine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	3.28e-05	0.000221	CcSEcCtD
Fluvoxamine—CYP2B6—Metabolism—APIP—chronic obstructive pulmonary disease	3.23e-05	0.000713	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	3.22e-05	0.00071	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.2e-05	0.000707	CbGpPWpGaD
Fluvoxamine—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.2e-05	0.000706	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—CXCL8—chronic obstructive pulmonary disease	3.18e-05	0.000702	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	3.18e-05	0.000702	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.17e-05	0.000701	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—APIP—chronic obstructive pulmonary disease	3.16e-05	0.000698	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.16e-05	0.000697	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—APIP—chronic obstructive pulmonary disease	3.15e-05	0.000696	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.15e-05	0.000696	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.13e-05	0.000691	CbGpPWpGaD
Fluvoxamine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	3.06e-05	0.000206	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—IL1B—chronic obstructive pulmonary disease	3.05e-05	0.000674	CbGpPWpGaD
Fluvoxamine—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.03e-05	0.000669	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	3.02e-05	0.000667	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.99e-05	0.00066	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	2.98e-05	0.000659	CbGpPWpGaD
Fluvoxamine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—chronic obstructive pulmonary disease	2.98e-05	0.000658	CbGpPWpGaD
Fluvoxamine—Asthenia—Prednisone—chronic obstructive pulmonary disease	2.98e-05	0.000201	CcSEcCtD
Fluvoxamine—CYP1A1—Metabolism—APIP—chronic obstructive pulmonary disease	2.98e-05	0.000658	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.94e-05	0.000649	CbGpPWpGaD
Fluvoxamine—Pruritus—Prednisone—chronic obstructive pulmonary disease	2.94e-05	0.000198	CcSEcCtD
Fluvoxamine—SLC6A3—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	2.92e-05	0.000644	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	2.92e-05	0.000644	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.92e-05	0.000644	CbGpPWpGaD
Fluvoxamine—SLC6A3—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	2.91e-05	0.000642	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.9e-05	0.00064	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.89e-05	0.000638	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.88e-05	0.000635	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	2.86e-05	0.000631	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	2.86e-05	0.000631	CbGpPWpGaD
Fluvoxamine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	2.84e-05	0.000191	CcSEcCtD
Fluvoxamine—CYP3A7—Metabolism—GC—chronic obstructive pulmonary disease	2.81e-05	0.000621	CbGpPWpGaD
Fluvoxamine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.79e-05	0.000616	CbGpPWpGaD
Fluvoxamine—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.76e-05	0.00061	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.75e-05	0.000607	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	2.75e-05	0.000607	CbGpPWpGaD
Fluvoxamine—Dizziness—Prednisone—chronic obstructive pulmonary disease	2.75e-05	0.000185	CcSEcCtD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	2.74e-05	0.000604	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.73e-05	0.000602	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	2.72e-05	0.000601	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	2.72e-05	0.000601	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.71e-05	0.000599	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.67e-05	0.00059	CbGpPWpGaD
Fluvoxamine—Vomiting—Prednisone—chronic obstructive pulmonary disease	2.64e-05	0.000178	CcSEcCtD
Fluvoxamine—Rash—Prednisone—chronic obstructive pulmonary disease	2.62e-05	0.000176	CcSEcCtD
Fluvoxamine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	2.62e-05	0.000176	CcSEcCtD
Fluvoxamine—CYP3A7—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.61e-05	0.000577	CbGpPWpGaD
Fluvoxamine—Headache—Prednisone—chronic obstructive pulmonary disease	2.6e-05	0.000175	CcSEcCtD
Fluvoxamine—ABCB1—Allograft Rejection—VEGFA—chronic obstructive pulmonary disease	2.58e-05	0.00057	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	2.51e-05	0.000554	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.49e-05	0.00055	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	2.47e-05	0.000546	CbGpPWpGaD
Fluvoxamine—Nausea—Prednisone—chronic obstructive pulmonary disease	2.47e-05	0.000166	CcSEcCtD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.46e-05	0.000543	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.46e-05	0.000543	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	2.44e-05	0.000539	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	2.44e-05	0.000538	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—APIP—chronic obstructive pulmonary disease	2.38e-05	0.000526	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—TGFB1—chronic obstructive pulmonary disease	2.37e-05	0.000523	CbGpPWpGaD
Fluvoxamine—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.36e-05	0.000522	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.33e-05	0.000514	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	2.24e-05	0.000495	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.23e-05	0.000493	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	2.22e-05	0.000491	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—TNF—chronic obstructive pulmonary disease	2.21e-05	0.000489	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.14e-05	0.000472	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.13e-05	0.000469	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.09e-05	0.000462	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.09e-05	0.000462	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.09e-05	0.000461	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GC—chronic obstructive pulmonary disease	2.08e-05	0.000459	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.06e-05	0.000456	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GC—chronic obstructive pulmonary disease	2.04e-05	0.00045	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GC—chronic obstructive pulmonary disease	2.03e-05	0.000449	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.97e-05	0.000436	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.96e-05	0.000432	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.93e-05	0.000427	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.92e-05	0.000425	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GC—chronic obstructive pulmonary disease	1.92e-05	0.000424	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	1.9e-05	0.00042	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.9e-05	0.000419	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.89e-05	0.000418	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.89e-05	0.000417	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.82e-05	0.000402	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.8e-05	0.000397	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.79e-05	0.000394	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.74e-05	0.000384	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.62e-05	0.000357	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.6e-05	0.000354	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.59e-05	0.00035	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.58e-05	0.000348	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	1.57e-05	0.000347	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.54e-05	0.000339	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GC—chronic obstructive pulmonary disease	1.53e-05	0.000339	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GCLC—chronic obstructive pulmonary disease	1.52e-05	0.000335	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.49e-05	0.000328	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.48e-05	0.000326	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.47e-05	0.000325	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	1.47e-05	0.000324	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.46e-05	0.000323	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.46e-05	0.000323	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.45e-05	0.000319	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.43e-05	0.000316	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.43e-05	0.000315	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CTGF—chronic obstructive pulmonary disease	1.39e-05	0.000306	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.35e-05	0.000299	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.34e-05	0.000297	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.33e-05	0.000294	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.28e-05	0.000282	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.27e-05	0.000281	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.26e-05	0.000278	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.22e-05	0.00027	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.22e-05	0.00027	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.17e-05	0.000258	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.16e-05	0.000257	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.15e-05	0.000253	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.14e-05	0.000251	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.14e-05	0.000251	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.12e-05	0.000248	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.11e-05	0.000246	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.11e-05	0.000245	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.1e-05	0.000243	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GCLC—chronic obstructive pulmonary disease	1.1e-05	0.000242	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.09e-05	0.000241	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.06e-05	0.000235	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.06e-05	0.000234	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.05e-05	0.000232	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.05e-05	0.000232	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.04e-05	0.000229	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.02e-05	0.000226	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CTGF—chronic obstructive pulmonary disease	1e-05	0.000222	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CTGF—chronic obstructive pulmonary disease	1e-05	0.000221	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.79e-06	0.000216	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.72e-06	0.000214	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	9.67e-06	0.000213	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	9.63e-06	0.000213	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	9.46e-06	0.000209	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	9.45e-06	0.000209	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.44e-06	0.000208	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.28e-06	0.000205	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.25e-06	0.000204	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CYP1A2—chronic obstructive pulmonary disease	9.23e-06	0.000204	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.07e-06	0.0002	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.79e-06	0.000194	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.72e-06	0.000193	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.59e-06	0.00019	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	8.49e-06	0.000187	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.38e-06	0.000185	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	8.28e-06	0.000183	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.91e-06	0.000175	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.9e-06	0.000174	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.88e-06	0.000174	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	7.83e-06	0.000173	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	7.81e-06	0.000172	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.77e-06	0.000171	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	7.74e-06	0.000171	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	7.74e-06	0.000171	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.71e-06	0.00017	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.7e-06	0.00017	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.61e-06	0.000168	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.59e-06	0.000168	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	7.56e-06	0.000167	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	7.34e-06	0.000162	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.27e-06	0.000161	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.24e-06	0.00016	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.22e-06	0.000159	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.17e-06	0.000158	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.14e-06	0.000158	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	7.12e-06	0.000157	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.09e-06	0.000156	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.07e-06	0.000156	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	7.06e-06	0.000156	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.96e-06	0.000154	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.86e-06	0.000151	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.72e-06	0.000148	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.71e-06	0.000148	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.69e-06	0.000148	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.68e-06	0.000148	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	6.61e-06	0.000146	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.56e-06	0.000145	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.51e-06	0.000144	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—ALB—chronic obstructive pulmonary disease	6.31e-06	0.000139	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.17e-06	0.000136	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	6.03e-06	0.000133	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—NOS3—chronic obstructive pulmonary disease	6.03e-06	0.000133	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.95e-06	0.000131	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.87e-06	0.00013	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.81e-06	0.000128	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.73e-06	0.000126	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.47e-06	0.000121	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.47e-06	0.000121	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.43e-06	0.00012	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.4e-06	0.000119	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.35e-06	0.000118	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.34e-06	0.000118	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.18e-06	0.000114	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.16e-06	0.000114	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	5.1e-06	0.000113	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.06e-06	0.000112	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.03e-06	0.000111	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.99e-06	0.00011	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.77e-06	0.000105	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.73e-06	0.000104	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ALB—chronic obstructive pulmonary disease	4.66e-06	0.000103	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	4.66e-06	0.000103	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.64e-06	0.000102	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.57e-06	0.000101	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ALB—chronic obstructive pulmonary disease	4.57e-06	0.000101	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ALB—chronic obstructive pulmonary disease	4.56e-06	0.000101	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.46e-06	9.85e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.37e-06	9.65e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—NOS3—chronic obstructive pulmonary disease	4.36e-06	9.63e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ALB—chronic obstructive pulmonary disease	4.31e-06	9.51e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.29e-06	9.47e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.26e-06	9.41e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	4.12e-06	9.09e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.04e-06	8.92e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.58e-06	7.9e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.53e-06	7.79e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	3.52e-06	7.78e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	3.44e-06	7.59e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	3.37e-06	7.44e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	3.29e-06	7.26e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.29e-06	7.26e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	3.24e-06	7.16e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	3.21e-06	7.09e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.12e-06	6.88e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	3.1e-06	6.85e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	3.07e-06	6.79e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.75e-06	6.06e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.63e-06	5.8e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	2.12e-06	4.68e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	2.03e-06	4.48e-05	CbGpPWpGaD
